Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV)
and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead …

Drug-target interaction (DTI) is the basis of drug discovery and design. It is time consuming
and costly to determine DTI experimentally. Hence, it is necessary to develop computational …

Motivation Traditional drug discovery and development are often time-consuming and high
risk. Repurposing/repositioning of approved drugs offers a relatively low-cost and high-…

Absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties play key roles
in the discovery/development of drugs, pesticides, food additives, consumer products, and …

Recent advances in DNA/RNA sequencing have made it possible to identify new targets
rapidly and to repurpose approved drugs for treating heterogeneous diseases by the ‘precise’ …

Drug combinations, offering increased therapeutic efficacy and reduced toxicity, play an
important role in treating multiple complex diseases. Yet, our ability to identify and validate …

Drug repurposing or repositioning is a technique whereby existing drugs are used to treat
emerging and challenging diseases, including COVID-19. Drug repurposing has become a …

Background Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has now been confirmed worldwide. Yet, COVID-…

There have been more than 2.2 million confirmed cases and over 120 000 deaths from the
human coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute …

Here we identify hundreds of new drug-disease associations for over 900 FDA-approved
drugs by quantifying the network proximity of disease genes and drug targets in the human (…